May 15 - 17, 2018
Merck Research Laboratories, Boston, MA


Plenary Speakers for 2018


Kendall Frazier, PhD, DVM

Director of Pathology & Senior Science Fellow, In Vitro In Vivo Translation, GSK

Leveraging Toxicology Experience to Solve Problems in the Developing World



John Leighton, PhD

Director, Division of Hematology Oncology Toxicology, Office of Hematology and Oncology Products, US Department of Health and Human Services

Recent Regulatory Updates from ICH and FDA: Implications for Oncology Drugs


 Speakers Confirmed for 2018

Barry Astroff, Director, Novartis Institutes for BioMedical Research (NIBR)

Vladimir Bantseev, Scientist/Toxicologist, Genentech

Giulio Barteselli, Associate Medical Director, Clinical Ophthalmology, Genentech

Sarah Campion, Senior Principal Scientist, Developmental and Reproductive Toxicology, Pfizer

Steven Cassar, Senior Scientist II, AbbVie

Darcey Clark, Principal Scientist, Toxicology, La Jolla Pharmaceutical Company

Paul Cornwell, Senior Research Scientist, Eli Lilly

Deidre Dalmas, Principal Scientist/Toxicologist, GSK

Krista Dobo, Senior Director Genetic Toxicology, Pfizer

Kevin French, Project Toxicologist, GSK

Claudette Fuller, Senior Principal Scientist, Merck

Maia Green, Principal Scientist, Merck

Larissa Lapteva, Associate Director, Division of Clinical Evaluation, Pharmacology and Toxicology, Office of Tissues and Advanced Therapies, CBER, FDA

Dong Lee, Head of Safety Pharmacology & Toxicology, Revolution Medicines

Steven Laing, Pathologist-Scientist, Genentech

Jonathan Maher, Senior Scientist, Discovery Toxicology, Genentech

Curtis Maier, Director, Immunology, GSK

Jenny Marlowe, Senior Director, Preclinical Development, bluebird bio

Mark Milton, Ophthalmology Therapeutic Area Head, PK Sciences, Novartis Institutes for BioMedical Research (NIBR)

Jeff Moffit, Executive Director, Toxicology, Bioverativ

John Nicolette, Senior Principal Research Scientist, AbbVie

Judith Prescott, Executive Director, Program Development, Safety Assessment, Merck

Haleh Saber, Deputy Director, (OHOP/DHOT), FDA



Proposed Sessions for the Discovery Toxicology Workshop

Session I:  When Knowledge is Power: Impactful Investigative Toxicology Case Studies

Session II:  Falling Off the Needle: Acute Anaphylactoid Reactions

Session III:  Hot Topics in Discovery Toxicology


Proposed Sessions for the Development Toxicology Workshop

Session IV:  Impurities and Occupational Exposure Limits / Health Hazard Categorization

Session V:   Regulatory Guidance Development and Updates

Session VI:  Key Learning from Recent Clinical Trial Experiences


Join our LinkedIn Group





Click here to register for the APT 2018 conference online.

APT 2018 will take place May 15-17, 2018 at:

Merck Research Laboratories

Boston, MA


The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3


Sign Up Today!

Privacy Policy